Veralto Co. (NYSE:VLTO – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $95.18.
VLTO has been the topic of several research reports. Citigroup lifted their price target on Veralto from $89.00 to $94.00 and gave the company a “neutral” rating in a research report on Monday, April 8th. Robert W. Baird lifted their price target on Veralto from $90.00 to $98.00 and gave the company a “neutral” rating in a research report on Thursday, April 25th. BMO Capital Markets boosted their target price on Veralto from $97.00 to $101.00 and gave the stock an “outperform” rating in a report on Thursday, April 25th. The Goldman Sachs Group initiated coverage on Veralto in a report on Friday, March 22nd. They issued a “buy” rating and a $104.00 target price on the stock. Finally, Stifel Nicolaus boosted their target price on Veralto from $92.00 to $97.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th.
Read Our Latest Stock Analysis on Veralto
Insider Activity at Veralto
Institutional Trading of Veralto
Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. bought a new position in Veralto during the fourth quarter valued at approximately $2,127,330,000. Capital International Investors bought a new position in Veralto during the fourth quarter valued at approximately $538,324,000. Brown Advisory Inc. bought a new position in Veralto during the fourth quarter valued at approximately $528,018,000. Impax Asset Management Group plc bought a new position in Veralto during the fourth quarter valued at approximately $347,827,000. Finally, Norges Bank bought a new position in Veralto during the fourth quarter valued at approximately $266,143,000. Hedge funds and other institutional investors own 91.28% of the company’s stock.
Veralto Price Performance
VLTO opened at $93.64 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 1.83 and a quick ratio of 1.56. Veralto has a 52-week low of $65.51 and a 52-week high of $95.56. The stock’s 50 day moving average price is $88.86 and its 200-day moving average price is $80.74.
Veralto (NYSE:VLTO – Get Free Report) last posted its earnings results on Tuesday, April 23rd. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.08. The business had revenue of $1.25 billion for the quarter, compared to analysts’ expectations of $1.23 billion. Veralto’s revenue was up 1.7% compared to the same quarter last year. Analysts forecast that Veralto will post 3.34 EPS for the current year.
Veralto Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Thursday, March 28th were given a dividend of $0.09 per share. This represents a $0.36 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date was Wednesday, March 27th.
Veralto Company Profile
Veralto Corporation provides water analytics, water treatment, marking and coding, and packaging and color services worldwide. It operates through two segments, Water Quality (WQ) and Product Quality & Innovation (PQI). The WQ segment offers precision instrumentation and water treatment technologies to measure, analyze, and treat water in residential, commercial, municipal, industrial, research, and natural resource applications through the Hach, Trojan Technologies, and ChemTreat brands.
See Also
- Five stocks we like better than Veralto
- Why is the Ex-Dividend Date Significant to Investors?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Golden Cross Stocks: Pattern, Examples and Charts
- Hilton Demonstrates Asset Light is Right for Investors
- Want to Profit on the Downtrend? Downtrends, Explained.
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Veralto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veralto and related companies with MarketBeat.com's FREE daily email newsletter.